UBS analyst Joshua Spector lowered the firm’s price target on Eastman Chemical (EMN) to $115 from $123 and keeps a Buy rating on the shares. The firm sees another challenging earnings cycle, with “largely ok” downstream earnings, while upstream/commodity earnings will be impacted by higher costs and likely weaker end of quarter demand, the analyst tells investors in a research note. UBS sees earnings misses to drive stocks down vs. provide relief.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMN:
- Eastman Chemical price target lowered to $99 from $105 at Piper Sandler
- Citi upgrades Eastman on relatively better position amid tariffs
- Eastman Chemical upgraded to Buy from Neutral at Citi
- Mizuho upgrades Eastman Chemical to Outperform on rising earnings estimates
- Eastman Chemical upgraded to Outperform from Neutral at Mizuho